Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.40 |
| ▸ | ACP1 | P24666 | 2/20 | 0.40 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6616722 | 0.83 | MAPT (0.49) | POLBMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2073787 | 0.81 | F10 (0.63) | PABPC1NPC1POLBMAPTMEN1 | |
| SCHEMBL12777439 | 0.78 | PABPC1 (0.58) | PABPC1NPC1POLBMAPTMEN1 | |
| SCHEMBL5167213 | 0.77 | F10 (0.58) | POLBMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL5164719 | 0.77 | F10 (0.48) | F10 | |
| SCHEMBL6726556 | 0.76 | PABPC1 (0.60) | PABPC1NPC1POLBMAPTMEN1 | |
| SCHEMBL2073687 | 0.73 | F10 (0.49) | PABPC1NPC1POLBMAPTMEN1 | |
| SCHEMBL6803185 | 0.72 | F10 (0.63) | POLBMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL6719866 | 0.71 | ROCK2 (0.62) | PABPC1NPC1POLBMAPTMEN1 | |
| SCHEMBL4735599 | 0.71 | ROCK2 (0.49) | NPC1POLBMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414456-B1 | PHENYL DERIVATIVES AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2011-12-28 | — | — | EP | claimed |
| US-7902223-B2 | For therapy and prophylaxis of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases | MERCK PATENT GMBH (DE) | 2011-03-08 | — | — | US | claimed |
| US-20040235828-A1 | Phenyl derivatives as factor XA Inhibitors | MERCK PATENTGESELLSCHAFT (DE) | 2004-11-25 | — | — | US | claimed |
| EP-1414456-B1 | PHENYL DERIVATIVES AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2011-12-28 | — | — | EP | disclosed |
| EP-1414456-B1 | PHENYL DERIVATIVES AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2011-12-28 | — | — | EP | disclosed |
| US-7902223-B2 | For therapy and prophylaxis of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases | MERCK PATENT GMBH (DE) | 2011-03-08 | — | — | US | disclosed |
| US-7902223-B2 | For therapy and prophylaxis of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases | MERCK PATENT GMBH (DE) | 2011-03-08 | — | — | US | disclosed |
| US-7902223-B2 | For therapy and prophylaxis of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases | MERCK PATENT GMBH (DE) | 2011-03-08 | — | — | US | disclosed |
| US-20040235828-A1 | Phenyl derivatives as factor XA Inhibitors | MERCK PATENTGESELLSCHAFT (DE) | 2004-11-25 | — | — | US | disclosed |
| EP-1414456-A1 | PHENYL DERIVATIVES AS FACTOR XA INHIBITORS | MERCK PATENT GmbH (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003013531-A1 | PHENYL DERIVATIVES AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2003-02-20 | — | — | WO | disclosed |
| WO-2003013531-A1 | PHENYL DERIVATIVES AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235828-A1 | Phenyl derivatives as factor XA Inhibitors | F11, F2, F12 | PABPC1 1141/4885NPC1 2046/4885POLB 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.